<DOC>
	<DOCNO>NCT00381550</DOCNO>
	<brief_summary>This phase II trial study well give 3-AP together fludarabine work treat patient myeloproliferative disorder ( MPD ) , chronic myelomonocytic leukemia ( CMML ) , accelerate phase blastic phase chronic myelogenous leukemia . Drugs use chemotherapy , 3-AP fludarabine , work different way stop growth cancer cell , either kill cell stop divide . 3-AP may help fludarabine work well make cancer cell sensitive drug . 3-AP fludarabine may also stop growth cancer cell block enzymes need cell growth . Giving 3-AP together fludarabine may kill cancer cell .</brief_summary>
	<brief_title>3-AP Fludarabine Treating Patients With Myeloproliferative Disorders , Chronic Myelomonocytic Leukemia , Accelerated Phase Blastic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy 3-AP ( Triapine® ) follow fludarabine phosphate patient myeloproliferative disorder chronic myelomonocytic leukemia aggressive phase transformation chronic myelogenous leukemia accelerate phase blast crisis . II . Determine toxicity regimen patient . III . Determine , preliminarily , effect regimen circulate leukemic cell genetics patient . Outline : This open-label study . Patients receive 3-AP ( Triapine® ) IV 4 hour follow fludarabine phosphate IV 30 minute day 1-5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients undergo bone marrow and/or peripheral blood collection baseline periodically study treatment molecular analysis Janus kinase 2 ( JAK2 ) mutation , GATA-1 mutation , expression death-inducer-obliterator ( Dido ) gene chromosome 20q . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Criteria : Not pregnant nursing Histopathologically confirm diagnosis 1 following : Myeloproliferative disorder ( MPDs ) aggressive phase transformation CML accelerate phase blast crisis Chronic myelomonocytic leukemia aggressive phase ( 519 % bone marrow blast ) transformation ( &gt; 20 % bone marrow blast ) Myeloproliferative disorder ( MPDs ) aggressive phase transformation , include follow : Polycythemia vera ( PV ) Essential thrombocythemia ( ET ) Myelofibrosis myeloid metaplasia Hypereosinophilic syndrome Atypical ( Philadelphia chromosome negative ) chronic myelogenous leukemia ( Ph CML ) Patients aggressive phase MPD ( PV , ET , Ph CML ) must meet ≥ 1 follow criterion : Marrow blast &gt; 5 % Peripheral blood blast plus progranulocytes &gt; 10 % New onset increase myelofibrosis New onset &gt; 25 % increase hepatomegaly splenomegaly New onset constitutional symptom ( fever , weight loss , splenic pain , bone pain ) Multilineage bone marrow failure Ineligible establish curative regimen , include stem cell transplantation ECOG performance status 02 Negative pregnancy test Fertile patient must use effective contraception No chronic toxicity prior chemotherapy &gt; grade 1 No history severe coronary artery disease Creatinine normal OR creatinine clearance &gt; = 60 mL/min AST ALT = &lt; 2.5 time normal Bilirubin = &lt; 2.0 mg/dL unless due leukemia , Gilbert 's syndrome , hemolysis No arrhythmia ( atrial flutter fibrillation ) require medication No uncontrolled congestive heart failure No dyspnea rest minimal exertion No severe pulmonary disease require supplemental oxygen No history allergic reaction attribute compound similar chemical biological composition 3AP ( Triapine® ) and/or fludarabine phosphate No lifethreatening illness No history mental deficit and/or psychiatric illness would preclude study compliance No 4 prior induction regimen ( 3 cytotoxic chemotherapy regimen ) At least 3 week since prior myelosuppressive cytotoxic agent ( 6 week mitomycin C nitrosoureas ) recover At least 1 week since prior nonmyelosuppressive treatment At least 48 hour since prior noncytotoxic agent peripheral blood leukemic cell count control , include limited following : Hydroxyurea Imatinib mesylate Interferon Mercaptopurine Cyclophosphamide At least 2 week since prior concurrent radiotherapy treat cancer At least 1 week since prior biologic therapy , include hematopoietic growth factor ( e.g. , epoetin alfa , darbepoetin alfa , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , interleukin3 , interleukin11 ) No concurrent chemotherapy treat cancer No concurrent immunotherapy treat cancer No know glucose6phosphate dehydrogenase [ G6PD ) deficiency ( G6PD screening require highrisk group ( i.e. , patient African , Asian , Mediterranean origin/ancestry ) ] No active heart disease No concurrent myeloid growth factor No active uncontrolled infection ( Infections active treatment control antibiotic allow ) No chronic hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>